• 1

    CDC: Reduced susceptibility of Staphylococcus aureus to vancomycin—Japan, 1996. .MMWR Morb Mortal Wkly Rep 46::624. ,1997. .

  • 2

    New antibiotic-resistant superbug found. Available at: http://www.newscientist.com/news/print.jsp?id=ns99992581. Accessed December 20. ,2003. .

  • 3

    Chambers HF: “Antimicrobial Agents: Protein Synthesis Inhibitors and Miscellaneous Antibacterial Agents,” in Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 10th Ed, ed by JG Hardman, LE Limbird, p 1262, McGraw-Hill, New York. ,2001. .

  • 4

    Vancomycin. Available at: http://www.cai.mcgill.ca/meded/drugdb/vancomycin/vancomycin_db.htm. Accessed December 27. ,2003. .

  • 5

    Vancomycin. Available at: http://www.molbio.princeton.edu/courses/mb427/2001/projects/02/vancomycin.htm. Accessed December 20. ,2003. .

  • 6

    Sterile vancomycin hydrochloride [USP package information insert], Abbott Laboratories, North Chicago, IL. ,1999. .

  • 7

    Vancomycin dosing. Available at: http://www.rxkinetics.com/vanco.html. Accessed December 19. ,2003. .

  • 8

    Vancomycin. Available at: http://www3.usal.es/~galenica/clinpkin/VANCOMYCINweb2.htm. Accessed December 19. ,2003. .

  • 9

    CDC: Interim guidelines for prevention and control of Staphylococcal infections associated with reduced susceptibility to vancomycin. .MMWR Morb Mortal Wkly Rep 46::626. ,1997. .

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10

    CDC issues recommendations for preventing spread of vancomycin resistance [news]. .Am J Health Syst Pharm 52::1272. ,1995. .

  • 11

    Rodman DP, McKnight JT, Rogers T, et al: The appropriateness of initial vancomycin dosing. .J Fam Pract 38::473. ,1994. .

  • 12

    Penzak SR, Gubbins PO, Rodvold KA, et al: Therapeutic drug monitoring of vancomycin in a morbidly obese patient. .Ther Drug Monit 20::261. ,1998. .

  • 13

    Moellering GR, Krogstad DJ, Greenblatt DJ: Vancomycin therapy in patients with impaired renal function: a nomogram for dosage. .Ann Intern Med 94::343. ,1981. .

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14

    Matzke GR, Zhanel GG, Guay DRP: Clinical pharmacokinetics of vancomycin. .Clin Pharmacokinet 11::257. ,1986. .

  • 15

    Matzke GR, Kovarik JM, Rybak MJ, et al: Evaluation of the vancomycin-clearance:creatinine-clearance relationship for predicting vancomycin dosage. .Clin Pharm 4::311. ,1985. .

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16

    Ackerman BH: Evaluation of three methods for determining initial vancomycin doses. .DICP 23::123. ,1989. .

  • 17

    Zokufa HZ, Podvold KA, Blum RA, et al: Simulation of vancomycin peak and trough concentrations using five dosing methods in 37 patients. .Pharmacotherapy 9::10. ,1989. .

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18

    Johnson S: Drawing vancomycin serum levels: is it really necessary? Available at: http://www.vh.org/adult/provider/pharmacyservices/PTNews/2002/09PTNews.html. Accessed December 27. ,2003. .

  • 19

    Tobin CM, Darville JM, Thomson AH, et al: Vancomycin therapeutic drug monitoring: is there a consensus view? the results of a UK National External Quality Assessment Scheme (UK NEQAS) for Antibiotic Assays questionnaire. .J Antimicrob Chemother 50::713. ,2002. .

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20

    Karam CM, McKinnon PS, Neuhauser MM, et al: Outcome assessment of minimizing vancomycin monitoring and dosing adjustments. .Pharmacotherapy 19::257. ,1999. .

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21

    Pou L, Rosell M, Lopez R, et al: Changes in vancomycin pharmacokinetics during treatment. .Ther Drug Monit 18::149. ,1996. .

  • 22

    Healy DP, Sahai JV, Fuller SH, et al: Vancomycin-induced histamine release and “red man syndrome”: comparison of 1- and 2-hour infusions. .Antimicrob Agents Chemother 34::550. ,1990. .

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23

    Farber BF, Moellering RC Jr: Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. .Antimicrob Agents Chemother 23::138. ,1983. .

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24

    Kirst HA, Thompson DG, Nicas TL: Historical yearly usage of vancomycin [letter]. .Antimicrob Agents Chemother 42::1303. ,1998. .

  • 25

    Jarvis WR: Epidemiology, appropriateness, and cost of vancomycin use. .Clin Infect Dis 26::1200. ,1998. .

Vancomycin

An Overview for the Podiatric Physician

Robert G. Smith Shoe String Podiatry, 22 Park Terr, Ormond Beach, FL 32174.

Search for other papers by Robert G. Smith in
Current site
Google Scholar
PubMed
Close
 DPM, RPh, CPed
Restricted access

An increased reliance on vancomycin to treat bacterial infections has led to the emergence of vancomycin-resistant organisms. The podiatric physician must select and use vancomycin with due caution. This article presents a general review of vancomycin’s pharmacology, pharmacokinetics, and dosing recommendations. Literature citations of clinically based evidence regarding the development and use of vancomycin nomograms are also presented. A vancomycin dosing nomogram is introduced as an effective tool for the prescribing podiatric physician. Appropriate use of the information presented may improve patient outcomes and enable the podiatric physician to treat patients with less effort and at a lower cost. (J Am Podiatr Med Assoc 94(4): 389–394, 2004)